dc.contributor.author | Crosbie, E | |
dc.contributor.author | MANCHANDA, R | |
dc.contributor.author | Ryan, N | |
dc.contributor.author | Arends, M | |
dc.contributor.author | Bosse, T | |
dc.contributor.author | Burn, J | |
dc.contributor.author | Cornes, J | |
dc.contributor.author | Crawford, R | |
dc.contributor.author | Eccles, D | |
dc.contributor.author | Frayling, I | |
dc.contributor.author | Ghaem-Maghami, S | |
dc.contributor.author | Hampel, H | |
dc.contributor.author | Kauff, N | |
dc.contributor.author | Kitchener, H | |
dc.contributor.author | Kitson, S | |
dc.contributor.author | McMahon, R | |
dc.contributor.author | Monahan, K | |
dc.contributor.author | Menon, U | |
dc.contributor.author | Møller, P | |
dc.contributor.author | Möslein, G | |
dc.contributor.author | Rosenthal, A | |
dc.contributor.author | Sasieni, P | |
dc.contributor.author | Seif, M | |
dc.contributor.author | Singh, N | |
dc.contributor.author | Skarrott, P | |
dc.contributor.author | Snowshill, T | |
dc.contributor.author | Steele, R | |
dc.contributor.author | Tischkowitz, M | |
dc.contributor.author | Manchester International Consensus Group | |
dc.contributor.author | Evans, D G | |
dc.date.accessioned | 2019-04-01T10:36:38Z | |
dc.date.available | 2019-03-06 | |
dc.date.available | 2019-04-01T10:36:38Z | |
dc.date.issued | 2019-03-28 | |
dc.identifier.issn | 1098-3600 | |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/56622 | |
dc.description.abstract | Purpose: There are no internationally agreed upon clinical
guidelines as to which women with gynecological cancer would
benefit from Lynch syndrome screening or how best to manage the
risk of gynecological cancer in women with Lynch syndrome.
The Manchester International Consensus Group was convened in
April 2017 to address this unmet need. The aim of the Group was
to develop clear and comprehensive clinical guidance regarding
the management of the gynecological sequelae of Lynch syndrome
based on existing evidence and expert opinion from medical
professionals and patients.
Methods: Stakeholders from Europe and North America worked
together over a two-day workshop to achieve consensus on best
practice.
Results: Guidance was developed in four key areas: (1) whether
women with gynecological cancer should be screened for Lynch
syndrome and (2) how this should be done, (3) whether there was
a role for gynecological surveillance in women at risk of Lynch
syndrome, and (4) what preventive measures should be recommended for women with Lynch syndrome to reduce their risk
of gynecological cancer.
Conclusion: This document provides comprehensive clinical
guidance that can be referenced by both patients and clinicians
so that women with Lynch syndrome can expect and receive
appropriate standards of care. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Nature | en_US |
dc.relation.ispartof | Genetics in Medicine | |
dc.subject | Lynch syndrome | en_US |
dc.subject | endometrial cancer | en_US |
dc.subject | screening | en_US |
dc.subject | surveillance | en_US |
dc.subject | guidance | en_US |
dc.title | The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome | en_US |
dc.type | Article | en_US |
dc.rights.holder | © The Author(s) 2019. | |
dc.identifier.doi | https://doi.org/10.1038/s41436-019-0489-y | |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
dcterms.dateAccepted | 2019-03-06 | |
rioxxterms.funder | Default funder | en_US |
rioxxterms.identifier.project | Default project | en_US |